Facioscapulohumeral Muscular Dystrophy (FSHD)

Condition Description

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disease that affects the muscles of your child's face, shoulders, upper arms, and lower legs. These muscles weaken and shrink (atrophy).

Active Trials

  • TRIAL TITLE: A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    DESCRIPTION: A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    SPONSOR: Avidity Biosciences

    INDICATION: Facioscapulohumeral Muscular Dystrophy (FSHD)

    STUDY PROTOCOL: AOC 1020-CS1

    PHASE: 1/2

    STATUS: Active

    RECRUITING PATIENTS: Yes

    Inquire About This Trial →

  • TRIAL TITLE: A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

    DESCRIPTION: AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in adult participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2).

    SPONSOR: Avidity Biosciences

    INDICATION: Facioscapulohumeral Muscular Dystrophy (FSHD)

    STUDY PROTOCOL: AOC 1020-CS2

    PHASE: 1/2

    STATUS: Active

    RECRUITING PATIENTS: No

    Inquire About This Trial →

Upcoming Trials

Past Trials